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Diagnostic and Therapeutic Immunology of Renal Cell Cancer 
Richard C. Klugo, MD* 
There is evidence that renal cell carcinoma can alter the host 
immunologic system in several modalities. Diagnostic im-
munologic monitoring techniques reviewed in this report 
include delayed cutaneous hypersensitivity reaction 
(DCHR), absolute peripheral lymphocyte count (APLC), 
lymphocyte mitogen response (LMR), T-lymphocyte popu-
lation (erythrocyte rosette), microcytotoxicity assay, in vitro 
monocyte chemotaxis, and serum blocking factors. 
Therapeutic immunologic modalities include xenogeneic 
immune ribonucleic acid (RNA), Intradermal BCG, pre-
operative transcatheter renal artery embolization, immune 
plasma transfusion, transfer factor, and polymerized auto-
logous tumor. 
Renal cell carcinoma has shown evidence of altering the 
host immunologic system in several modalities. Attempts to 
monitor the stage of the cancer as well as to alter its 
immunologic suppression have met with some encouraging 
results. Diagnostic immunologic monitoringtechniques in-
clude delayed cutaneous hypersensitivity reaction (DCHR), 
absolute peripheral lymphocyte count (APLC), lymphocyte 
mitogen response (LMR), T- lymphocyte populat ion 
(erythrocyte rosette), microcytotoxicity assay, in vitro mono-
cyte chemotaxis, and serum blocking factors. 
Therapeutic immunologic alteration has been limited to use 
in stage IV disease. The modalities of immunotherapy 
include xenogeneic immune ribonucleic acid (RNA), intra-
dermal BCG, preoperative transcatheter renal artery embol-
ization, immune plasma transfusion, transfer factor, and 
polymerized autologous tumor. 
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Diagnostic Immunology 
Delayed cutaneous hypersensitivity reaction 
Evaluation of patients with common recall antigens (SKSD, 
PPD, mumps, Candida, histoplasmin) revealed a 35-40% 
response with the positive antigen varying. Nephrectomy 
and treatment with BCG appear to improve this response to 
75-80% in patients with no residual disease.''•^ In patients 
with residual disease, the average response may be im-
proved, but the percentages vary widely with the antigen 
and with the type of immunologic manipulation. Recall 
antigen response depends on previous exposure to the 
antigen, nutritional status, and, to a variable degree, on the 
stage of the cancer. The only consistent prognostic indicator 
is anergy, which is usually present in severely advanced 
disease. The use of recall antigens has very little consistent 
value as a prognostic indicator, but may be useful as an 
adjunctive indicator of response to immune manipulation. 
Absolute peripheral lymphocyte count 
Absolute peripheral lymphocyte counts appear to be signifi-
cantly lower in patients with metastatic disease and con-
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tinue to decline despite nephrectomy when studied 
sequentially. Patients with localized disease have a tempo-
rary depression for four weeks following nephrectomy, but 
their counts then return to preoperative levels and remain 
stable. Pretreatment counts do not appear to correlate 
directly with prognosis in renal cell carcinoma. Sequential 
pretreatment and posttreatment studies are needed to indi-
cate persistent disease and prognosis.^ 
T-lymphocyte population 
In patients with metastatic renal cell cancer, the capacity of 
T-lymphocytes to form E rosettes with sheep red blood cells 
is significantly impaired. While renal arterial embolization 
does not appear to alter the percentage of T-lymphocytes," 
nephrectomy significantly increases the level in peripheral 
blood within two weeks. Pre-nephrectomy studies of T-
lymphocyte levels in the renal artery and vein reveal a 
marked decrease of T-lymphocytes in the ipsilateral renal 
vein when compared to the ipsilateral renal artery and the 
contralateral renal vein.* This suggests a suppression of E 
rosette formation related either to antigen excess or antigen 
antibody complexes directly related to the tumor. Thus, as 
might be expected, nephrectomy raises peripheral T-lym-
phocyte counts, whereas arterial embolization does not 
alter them.* 
Lymphocyte mitogen response 
Evaluation of lymphocyte response to mitogens in vitro 
shows generally depressed counts before nephrectomy 
when compared wfth normal patients.^ '^  However, ft one 
does sequential studies, considerable variations in these 
counts occur without any evident correlation to clinical 
changes.^  Such variability reduces the reliability of this 
study as an accurate parameter of immune alterations. 
Microcytotoxicity assay 
Cell-mediated immunity as measured by in vitro evaluation 
of lymphocyte mediated cytoloysis of human renal car-
cinoma cells was present in patients with clinical evidence 
of residual renal cancer. Patients with no clinical evidence 
of renal cancer appear to lose their cell-mediated response 
as early as 17 months after nephrectomy. However, one 
patient who was clinically free of renal cancer for 24 years 
showed a persistent cell-mediated immune response.*'''This 
response may be improved by converting lymphocytes 
to effector eel Is with xenogeneic immune RN A.*'^  Rad iation 
therapy also appears capable of abrogating this cell-medi-
ated response. Such studies would suggest that the cellular 
response is linked to the presence of grossly discernible 
tumor, although it is more likely linked to the presence of 
tumor antigen, whether gross or microscopic, clinically 
discernible or not. The possibil ity of using this parameter to 
determine the need for adjuvant therapy should be studied 
further. 
Monocyte chemotaxis in vitro 
Monocyte chemotaxis was depressed in patients with lo-
calized (Stage I) renal cell carcinoma when compared to 
controls, but returned to normal levels three months after 
nephrectomy. Patients with locally extensive disease, in-
cluding invasion of Gerota's capsule or extension into the 
renal vein show significant depression of monocyte chem-
otaxis, which is delayed for as long as six months after 
nephrectomy; in a small percentage of patients it does not 
return to normal. In patients with matastasis depression of 
chemotaxis does not return to normal after nephrectomy. '^'"' 
Since monocyte chemotaxis appears to correlate well wfth 
tumor stage, persistent depression beyond six months after 
nephrectomy would suggest the presence of clinically un-
dected neoplasm. 
Serum blocking factors 
Serum blocking factors have been demonstrated by several 
investigators studying patients with renal cell carcino-
ma.*''''" The depression of T-lymphocytes in the renal 
venous effluent would suggest that an excess of tumor 
antigen or antigen-antibody complexes is present in the 
serum. Electrophoresis of serum protein indicates that the 
alpha-2-globulin fraction is elevated in patients with meta-
stasis, becomes progressively immunosuppressive, and in-
creases as the disease advances.^  Blocking activity of the 
serum in patients with renal cell carcinoma using the 
microcytotoxicity assay shows considerable activity in the 
presence of tumor, both local and metastatic. In patients 
with localized disease, it disappears within six months after 
nephrectomy, whereas in patients with residual disease, 
nephrectomy does not alter this response. 
Therapeutic Immunology 
Xenogeneic immune RNA 
Xenogeneic immune ribonucleic acid (RNA) can increase 
cytotoxic activity of lymphocytes in patientswith metastatic 
renal cell carcinoma. Lymphocytes incubated without 
xenogeneic immune RNA or with RNA from sheep immu-
nized with Freund's adjuvant alone did not increase cytotox-
icity. Normal lymphocytes are moderately cytotoxic to renal 
carcinoma cells, but this response may be related to histo-
compatability in an allogeneic system. Preliminary clinical 
results indicate that this modality has a low level of toxicity 
and may be able to stabilize metastatic disease. However, 
no evidence of tumor regression was noted with up to 17 
months of therapy.*'^  It is difficult to determine the effect of 
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this therapy on renal cell carcinoma, particularly within the 
first 12 months after nephrectomy. Its primary role wil l 
most likely be with minimal residual disease or as an 
adjuvant to chemotherapy. Its potential hazards include the 
possible induction of cytotoxic immunity against normal 
tissues or the enhancement of tumor immunity. 
Intradermal BCG 
Preliminary studies of BCG response in advanced renal cell 
carc inoma offer some opt imism for its use in immu-
notherapy. Not only is immunization with BCG able to 
convert patients from PPD negative to positive, but evi-
dence of measurable reduction in the size of pulmonary 
lesions was also documented. Lesions in bone and brain 
appear to progress in the presence of a response from 
pulmonary lesions. Toxicity includes erythema at the site of 
previous injections, superficial ulcers at the injection site, 
low-grade fever, and sweats and chills (two-three days.) 
Similar therapy in other tumor systems has resulted in 
tumor enhancement and the induction of anergy.'"'•'^ 
Preoperative transcatheter embolization 
Although transcatheter renal artery embolization has been 
used to reduce tumor bulk and bleeding, preliminary studies 
indicate an improved response of metastatic lesions after 
nephrectomy.^" In patients with metastatic renal cancer, 
peripheral B lymphocyte counts do not differ from normals 
and are not modified by nephrectomy or embolization. 
Basal T lymphocyte counts were depressed when compared 
to normals but were not modftied after embolization. How-
ever, significant improvement in T lymphocyte counts was 
noted within 15 days after nephrectomy."'* 
These results do not appear to differ from similar studies 
completed in patients who underwent nephrectomy without 
preoperative renal artery embolization. While improved 
clinical response of metastasis in patientswith preoperative 
embolization cannot easily be explained in view of those 
studies, sequential studies with longer postnephrectomy 
evaluation might provide additional information. Patients 
who undergo renal artery embolization have considerable 
hyperthermia until nephrectomy is completed. Since hyper-
thermia can produce tumor necrosis, this may be the 
mechanism for the improved response of metastatic disease 
in these patients. Studies of circulating immune complexes 
bythe ^ Iq binding assay suggest a marked alteration in the 
amount and solubility of these complexes after renal artery 
infarction. Subsequent nephrectomy may allow excess 
tumor antigen or altered antigen-antibody complexes to 
induce a heightened tumor-directed, cell-mediated re-
sponse to metastatic lesions. 
Immune plasma transfusion 
Repressor plasma transfusion has been used to treat meta-
static lesions with variable response. In a recent report one 
of four patients responded completely when treated with 
this form of passive immunotherapy.'* 
Transfer factor 
Transfer factor isa dialyzable extract of human lymphocytes 
used to develop adoptive immunity in patients with meta-
static renal cell carcinoma. Early evaluation of clinical trials 
revealed no objective regression but possibly some stabil-
ization of disease for short periods.^* 
Polymerized autologous tumor 
Intradermal immunization with autologous polymerized, 
homogenized tumor was used to treat 21 patients with 
pulmonary metastasis,''^ and five patients showed complete 
regression for up to 25 months. As a result, this would 
appear to be the most promising of the immunotherapy 
modalities. Although additional information indicates a 
reduction in the response rates (8 CR in 57 patients), 
the longest, disease-free remission recorded thus far is 45 
months.''* 
Summary 
Immunodiagnostic techniques include more emphasis on 
the use of monocyte chemotaxis and T-lymphocyte, B-
lymphocyte populations. The use of microcytotoxicity as-
says and evaluation for serum blocking factors has demon-
strated the possibility of detecting residual tumor antigen 
which is otherwise not clinically evident. Recall antigen 
response and lymphocyte mitogen response are more in-
consistent and unreliable for evaluating the stage of the 
tumor or detecting evidence of clinically occult tumor. 
Immunotherapy requires further study of the response of 
polymerized autologous tumor and preoperative trans-
catheter embolization. Trials with xenogeneic immune 
RNA and transfer factor wil l require longer term evaluation 
with larger patient populations. 
Modalities also considered for combined implementation 
would include repressor plasma transfusion (passive) and 
BCG intradermal nonspecific (active) or polymerized auto-
logous antigen (specific active). 
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